MDM2 and cancer: We, therefore, reasoned that other MDM2 inhibitors should be equally as effective, and tested two additional MDM2 inhibitors, i.e., Milademetan (DS-3032) and AMG232, both of which are currently evaluated in clinical trials for patients diagnosed with acute myeloid leukemia (AML) and other types of cancers (e.g., NCT03671564 and NCT02016729).